Drugs and Supplements 

Drugmaker’s ties to nonprofits pose ‘conflict of interest’

A leading advocacy group for Alzheimer’s patients has stopped accepting funding from a Southern California drugmaker following a CNN investigation into the company that sparked a government probe. The CNN report on Avanir Pharmaceuticals showed that its drug Nuedexta has not been extensively studied among the elderly and may be unnecessary or even unsafe for them. Nuedexta, which treats a rare laughing and crying disorder known as pseudobulbar affect, or PBA, is not approved to treat dementia patients unless they also suffer from PBA. Yet Avanir’s financial success has been…

Read More